Aurinia Pharmaceuticals Inc.
$15.96
▲
0.9%
2026-04-21 05:29:00
www.auriniapharma.com
NGM: AUPH
Explore Aurinia Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.12 B
Current Price
$15.96
52W High / Low
$16.54 / $7.29
Stock P/E
7.38
Book Value
$4.39
Dividend Yield
—
ROCE
16.2%
ROE
59.91%
Face Value
—
EPS
$2.07
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
128
Beta
1.52
Debt / Equity
12.87
Current Ratio
5.25
Quick Ratio
4.76
Forward P/E
19.22
Price / Sales
7.4
Enterprise Value
$1.77 B
EV / EBITDA
13.06
EV / Revenue
6.26
Rating
Buy
Target Price
$17
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
| 2. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 3. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 4. | Dyne Therapeutics, Inc. | $20.02 | — | $3.37 B | — | -41.2% | -55.71% | $25 / $7.38 | $5.89 |
| 5. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 6. | Arbutus Biopharma Corporation | $4.6 | — | $899.2 M | — | -30.53% | -38.52% | $5.1 / $2.94 | $0.4 |
| 7. | Bone Biologics Corporation | $1.38 | — | $2.5 M | — | -60.16% | -70.17% | $6.75 / $1.05 | $3 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 77.11 M | 73.47 M | 70.01 M | 62.47 M | 59.87 M | — |
| Operating Profit | 33.24 M | 29.75 M | 20.2 M | 23.38 M | 13.68 M | — |
| Net Profit | 210.79 M | 31.55 M | 21.51 M | 23.34 M | 1.43 M | — |
| EPS in Rs | 1.59 | 0.24 | 0.16 | 0.18 | 0.01 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 283.06 M | 235.13 M | 175.51 M | 134.03 M |
| Operating Profit | 106.56 M | 18.42 M | -91.69 M | -111.47 M |
| Net Profit | 287.2 M | 5.75 M | -78.02 M | -108.18 M |
| EPS in Rs | 2.16 | 0.04 | -0.59 | -0.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 751.59 M | 550.64 M | 548.06 M | 470.86 M |
| Total Liabilities | 170.26 M | 173.17 M | 170.11 M | 65.42 M |
| Equity | 581.33 M | 377.48 M | 377.95 M | 405.44 M |
| Current Assets | 491.97 M | 446.6 M | 424.8 M | 442.54 M |
| Current Liabilities | 93.72 M | 97.76 M | 77.19 M | 46.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 135.66 M | 44.39 M | -33.46 M | -79.53 M |
| Investing CF | -32.77 M | 39.26 M | -6.71 M | -60.63 M |
| Financing CF | -106.11 M | -49.09 M | -5.13 M | 2.43 M |
| Free CF | 135.41 M | 44.11 M | -34.18 M | -79.82 M |
| Capex | -0.25 M | -0.28 M | -0.72 M | -0.29 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 33.97% | 30.95% | — | — |
| Earnings Growth % | 107.37% | 27.88% | — | — |
| Profit Margin % | 2.45% | -44.45% | -80.71% | — |
| Operating Margin % | 7.83% | -52.24% | -83.17% | — |
| Gross Margin % | 87.99% | 91.94% | 95.77% | — |
| EBITDA Margin % | 13.49% | -35.92% | -77.33% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.